Hemostemix (CVE:HEM) Reaches New 52-Week Low – Here’s What Happened

Hemostemix Inc. (CVE:HEM)’s stock price reached a new 52-week low during trading on Friday . The company traded as low as C$0.08 and last traded at C$0.08, with a volume of 300926 shares changing hands. The stock had previously closed at C$0.09.

Hemostemix Stock Performance

The company has a quick ratio of 0.48, a current ratio of 1.54 and a debt-to-equity ratio of -99.52. The business has a 50 day moving average price of C$0.09 and a two-hundred day moving average price of C$0.09. The stock has a market cap of C$15.08 million, a P/E ratio of -2.96 and a beta of 0.25.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.